Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.

12 Issues per year


IMPACT FACTOR 2016: 3.432

CiteScore 2016: 2.21

SCImago Journal Rank (SJR) 2016: 1.000
Source Normalized Impact per Paper (SNIP) 2016: 1.112

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 47, Issue 3 (Mar 2009)

Issues

Dipeptidyl-peptidase IV and B-type natriuretic peptide. From bench to bedside

Marc Vanderheyden
  • 1Cardiovascular Center, Onze Lieve Vrouwziekenhuis, Aalst, Belgium
/ Jozef Bartunek
  • 2Cardiovascular Center, Onze Lieve Vrouwziekenhuis, Aalst, Belgium
/ Marc Goethals
  • 3Cardiovascular Center, Onze Lieve Vrouwziekenhuis, Aalst, Belgium
/ Sofie Verstreken
  • 4Cardiovascular Center, Onze Lieve Vrouwziekenhuis, Aalst, Belgium
/ Anne-Marie Lambeir
  • 5Laboratory of Medical Biochemistry, Department of Pharmaceutical Sciences, University of Antwerp, Antwerp, Belgium
/ Ingrid De Meester
  • 6Laboratory of Medical Biochemistry, Department of Pharmaceutical Sciences, University of Antwerp, Antwerp, Belgium
/ Simon Scharpé
  • 7Laboratory of Medical Biochemistry, Department of Pharmaceutical Sciences, University of Antwerp, Antwerp, Belgium

Abstract

B-type natriuretic peptide (BNP) has emerged as a reliable biomarker in patients with congestive heart failure. The mature, biologically active B-type natriuretic peptide, BNP(1–32), is cleaved by corin from the 108 amino acid proBNP. However, in vivo as well as in vitro data demonstrated that this BNP(1–32) might be an ideal substrate for the endogenous aminopeptidase, dipeptidyl-peptidase IV (DPP IV). DPP IV removes the two amino terminal amino acids (Ser Pro) from BNP(1–32) to produce BNP(3–32), which has been detected in plasma of patients with congestive heart failure. The biological effects of BNP(3–32) remain undetermined. In cultured human cardiomyocytes and fibroblasts, equimolar concentrations of BNP(1–32) and BNP(3–32) both exert similar biological effects, as evidenced by their cGMP (cyclic guanylate monophosphate) generating capacity. However, in a canine model, intravenous BNP(3–32) infusion resulted in less natriuresis, diuresis, and vasodilation compared to intravenous infusion of BNP(1–32). The clinical relevance of these observations might be important for patients in whom the plasma BNP concentrations, measured by commercially available immunoassays, are high. Further studies exploring whether DPP IV inhibitors increase the bioavailability of BNP(1–32), delay the progression of heart failure, and increase the efficacy of exogenous administration of BNP(1–32) in decompensated heart failure are needed.

Clin Chem Lab Med 2009;47:248–52.

Keywords: B-type natriuretic peptide; CD26; congestive heart failure; dipeptidyl-peptidase IV

About the article

Corresponding author: Marc Vanderheyden, Cardiovascular Center, Onze Lieve Vrouwziekenhuis, Moorselbaan 164, 9300 Aalst, Belgium Phone: +32-53-724439,


Received: 2008-10-08

Accepted: 2009-01-19

Published in Print: 2009-03-01


Citation Information: Clinical Chemistry and Laboratory Medicine, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.2009.065.

Export Citation

©2009 by Walter de Gruyter Berlin New York. Copyright Clearance Center

Comments (0)

Please log in or register to comment.
Log in